Study wrapper · #553
Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days.
Editor's note
This is a regulatory toxicology study directly relevant to GHRP-6: CIGB-500 is a formulation whose active ingredient is GHRP-6. Beagle dogs received daily intravenous doses (300, 1000, 2000 µg/kg/day) for 28 days. Researchers reported transient, dose-related signs at the higher doses (hypersalivation, reduced activity, lowered heart rate, pale gums, head erythema) that they classified as non-adverse and reversible, with no adverse macroscopic or microscopic tissue changes; the no-observed-adverse-effect level was set at the top dose, 2000 µg/kg/day. This is single-species preclinical safety data, not efficacy, and dog tolerability does not establish human safety. It is worth surfacing as GHRP-6-specific toxicology context, framed as preclinical. Note the transient heart-rate reduction observed at all dose levels.
Plain-language abstract
This study assessed the safety of a GHRP-6-based drug (called CIGB-500) given to beagle dogs. Dogs received one of three daily doses through a vein for 28 days and were compared with untreated controls. At the two higher doses, some dogs showed temporary effects — extra salivation, reduced activity, a slower heart rate, pale gums, and redness on the head — but these were short-lived and, according to the researchers, did not amount to harm; the tissues showed no lasting damage under the microscope. A drop in heart rate was noted at all dose levels and returned to normal by the end of the recovery period at the highest dose. The researchers concluded the drug was well tolerated up to the highest dose tested and set that as the no-adverse-effect level. This is an animal safety study, not a study of benefits, and results in dogs do not confirm safety in people.